Drugs / D-Penicillamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00552630 | Sep 2007 → ? | lead poisoning, vitamin D deficiency | FDA Office of Orphan Products Development | Withdrawn | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT03106948 Comparator | Feb 2017 → Jan 2018 | vascular occlusion disorder | Southeast Renal Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT07465718 Comparator | Sep 2026 → Feb 2028 expected | Wilson disease | Orphalan | Recruiting | No outcome recorded |
| Phase 3 | NCT03660059 Background | Sep 2018 → Apr 2021 | rheumatoid arthritis | Astellas Pharma Inc | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D-Penicillamine | “hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.” NCT03660059 ↗3“d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks” NCT00552630 ↗ “D-Penicillamine” NCT03106948 ↗ |
| Known as | DPA | “d-Penicillamine (DPA) is currently the only approved first line chelator for the treatment of WD” NCT07465718 ↗ |